• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Valsartan. Just a second-line antihypertensive drug.缬沙坦。只是一种二线抗高血压药物。
Can Fam Physician. 1999 Nov;45:2626-8, 2630-3.
2
Valsartan: new preparation. Just a second-line antihypertensive drug.
Prescrire Int. 1998 Oct;7(37):144-5.
3
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.血管紧张素II受体拮抗剂与心力衰竭:血管紧张素转换酶抑制剂仍是一线选择。
Prescrire Int. 2005 Oct;14(79):180-6.
4
Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
J Hypertens. 2006 Aug;24(8):1679-81; author reply 1681-2. doi: 10.1097/01.hjh.0000239307.86248.80.
5
[New effective dosage of valsartan. High dosage--effective against high blood pressure].
MMW Fortschr Med. 2007 Nov 15;149(46):52-3.
6
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.缬沙坦添加至背景性血管紧张素转换酶抑制剂治疗对心力衰竭患者的影响:缬沙坦心力衰竭试验(Val-HeFT)结果
Eur J Heart Fail. 2004 Dec;6(7):937-45. doi: 10.1016/j.ejheart.2004.09.005.
7
Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT).高血压的固定复方疗法:聚焦缬沙坦/氢氯噻嗪复方制剂(代文/氢氯噻嗪)
Expert Rev Cardiovasc Ther. 2003 Sep;1(3):335-43. doi: 10.1586/14779072.1.3.335.
8
Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.联合治疗在高血压治疗中的作用:聚焦缬沙坦联合氨氯地平
Adv Ther. 2008 Apr;25(4):300-20. doi: 10.1007/s12325-008-0042-x.
9
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.维格列汀是一种新型二肽基肽酶IV抑制剂,在健康受试者中,它与抗高血压药物氨氯地平、缬沙坦和雷米普利不存在药代动力学相互作用。
J Clin Pharmacol. 2008 Jan;48(1):85-95. doi: 10.1177/0091270007307880. Epub 2007 Nov 6.
10
Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction.非降压剂量的缬沙坦和依那普利联合使用可提高伴有内皮功能障碍的自发性高血压大鼠的存活率。
J Renin Angiotensin Aldosterone Syst. 2000 Jun;1(2):151-8. doi: 10.3317/jraas.2000.019.

本文引用的文献

1
Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension.缬沙坦与赖诺普利相比在老年原发性高血压患者中的长期疗效和耐受性
Clin Exp Hypertens. 1997 Nov;19(8):1263-85. doi: 10.3109/10641969709083217.
2
Valsartan. A review of its pharmacology and therapeutic use in essential hypertension.缬沙坦。其药理学及在原发性高血压治疗应用的综述。
Drugs. 1997 Aug;54(2):299-311. doi: 10.2165/00003495-199754020-00009.
3
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide.
Eur J Clin Pharmacol. 1997;52(3):173-7. doi: 10.1007/s002280050270.
4
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).氯沙坦与卡托普利治疗65岁以上心力衰竭患者的随机试验(老年氯沙坦评估研究,ELITE)
Lancet. 1997 Mar 15;349(9054):747-52. doi: 10.1016/s0140-6736(97)01187-2.
5
Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide.缬沙坦,一种新型血管紧张素II受体拮抗剂:一项比较缬沙坦与赖诺普利及氢氯噻嗪咳嗽发生率的双盲研究。
J Clin Pharmacol. 1997 Feb;37(2):101-7. doi: 10.1002/j.1552-4604.1997.tb04767.x.
6
Angiotensin converting enzyme inhibition corrects Na+/H+ exchanger overactivity in essential hypertension.
Am J Hypertens. 1997 Jan;10(1):84-93. doi: 10.1016/s0895-7061(96)00296-8.
7
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril.缬沙坦,一种用于治疗原发性高血压的新型血管紧张素II拮抗剂:与安慰剂和依那普利相比的疗效和安全性。
J Hypertens. 1996 Sep;14(9):1147-51. doi: 10.1097/00004872-199609000-00016.
8
The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension.
Clin Ther. 1996 Sep-Oct;18(5):797-810. doi: 10.1016/s0149-2918(96)80040-3.
9
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.缬沙坦,一种用于治疗原发性高血压的新型血管紧张素II拮抗剂:与氨氯地平疗效和安全性的对比研究。
Clin Pharmacol Ther. 1996 Sep;60(3):341-6. doi: 10.1016/S0009-9236(96)90061-2.

缬沙坦。只是一种二线抗高血压药物。

Valsartan. Just a second-line antihypertensive drug.

出版信息

Can Fam Physician. 1999 Nov;45:2626-8, 2630-3.

PMID:10587770
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2328654/
Abstract

Valsartan (Diovan) is an antihypertensive drug belonging to the family of angiotensin II receptor antagonists. At a dose of 40 mg/d, its antihypertensive effect is inconsistent. At 80 mg/d its effect on blood pressure, its adverse effects, and its contraindications (mainly pregnancy and renal artery stenosis) are similar to those of angiotensin-converting enzyme (ACE) inhibitors, except that coughing is rarer with valsartan than with ACE inhibitors. Valsartan has no demonstrated advantage over losartan, another angiotensin II antagonist. Valsartan has not been shown to prevent complications of arterial hypertension, and its use is, therefore, less well validated than that of diuretics and beta-blockers.

摘要

缬沙坦(代文)是一种属于血管紧张素II受体拮抗剂类别的抗高血压药物。剂量为40毫克/天时,其降压效果不一致。剂量为80毫克/天时,其对血压的作用、不良反应及禁忌证(主要是妊娠和肾动脉狭窄)与血管紧张素转换酶(ACE)抑制剂相似,只是缬沙坦引起咳嗽比ACE抑制剂少见。缬沙坦与另一种血管紧张素II拮抗剂氯沙坦相比并无已证实的优势。缬沙坦尚未显示出可预防动脉高血压并发症,因此,其应用的有效性不及利尿剂和β受体阻滞剂。